Detalhe da pesquisa
1.
Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma.
Invest New Drugs
; 31(2): 425-34, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22864522
2.
Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers.
Oncoimmunology
; 10(1): 1943253, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34290906
3.
A Phase I Study of Pegylated Arginine Deiminase (Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade Glioma.
Clin Cancer Res
; 25(9): 2708-2716, 2019 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30796035
4.
Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers.
J Clin Oncol
; 35(16): 1778-1785, 2017 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28388291
5.
Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial.
JAMA Oncol
; 3(1): 58-66, 2017 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27584578
6.
Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging.
Cancer Res
; 74(3): 896-907, 2014 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24285724